Neurol Sci. 2012 Sep 7. [Epub ahead of print]
Ojeda-López C, Cervantes-Arriaga A, Rodríguez-Violante M, Corona T.
Source
Department
of Neurology, Instituto Nacional de Neurología y Neurocirugía,
Insurgentes Sur 3877, Col. La Fama, Tlalpan, 14269, Mexico, DF, Mexico
Abstract
The
objective of this study is to assess the effect of smoking and caffeine
intake in the dosage of dopaminergic replacement therapy. Patients were
recruited from the movement disorders clinic of the National Institute
of Neurology and Neurosurgery in Mexico City. An
interviewer-administered structured questionnaire was given to all
subjects regarding their smoking and caffeine drinking habits.
Dopaminergic replacement therapy information was collected and
levodopa, dopamine agonists, and levodopa equivalent daily doses were
calculated. 146 Parkinson's disease patients (50 % female) were
included. All patients were on antiparkinsonian treatment, with a mean
levodopa equivalent daily dose (LEDD) of 550.2 ± 408. Patients were
stratified according to smoking and caffeine drinking status. 104
(71.2 %) of the patients were "never smokers", 33 (22.6 %) were "former
smokers" and 9 (6.2 %) were "current smokers". 40 (27.4 %) patients
reported no history of caffeine intake, 36 (24.7 %) were former
consumers and 70 (47.9 %) were current caffeine drinkers. No
association between LEDD and smoking or caffeine intake was found. A
weak positive correlation (r = 0.22, p < 0.04) was found between the
daily dose of pramipexole and the daily intake of caffeine. LEDD,
levodopa daily dose and dopamine agonist daily dose were not related to
smoking or caffeine intake status. We found a weak correlation between
caffeine daily intake and pramipexole dose. Further prospective
exploration is needed to address the interaction of concomitant A2A
antagonism induced by caffeine intake and dopaminergic replacement
therapy.
No comments:
Post a Comment